Ginseng intestinal metabolite-I (GIM-I) reduces doxorubicin toxicity in the mouse testis.
The protective effect of ginseng intestinal metabolite-I (GIM-I) against doxorubicin-induced testicular toxicity was investigated in 5-week-old ICR male mice. GIM-I was administered orally to mice at a dose of 50 mg/kg daily for 4 weeks. From the second week, doxorubicin was coadministered intraperitoneally to the animals at a dose of 3 mg/kg once a week for 3 weeks (a total of 9 mg/kg). The body weight, spermatogenic activities (Sertoli cell, repopulation, and epididymal indices), and serum levels of lactate dehydrogenase (LDH) and creatine phosphokinase (CPK) were significantly decreased by doxorubicin treatment (P<0.01), while the combined treatment of GIM-I with doxorubicin resulted in parameters similar to the control. In the testes of doxorubicin-treated animals, almost all of the germ cells disappeared and were replaced by fibrinoid debris in the seminiferous tubules. Germ cell injury was significantly attenuated by GIM-I coadministration. The mRNA for phospholipid hydroperoxide glutathione peroxidase (PHGPx), a testis-specific antioxidant, was greatly decreased by doxorubicin treatment, and less decreased with GIM-I coadministration. These findings indicate that GIM-I may be partially protective against doxorubicin-induced testicular toxicity.
Kang
Jong- Koo
J
College of Veterinary Medicine, Chungbuk National University, Cheongju 361-763, South Korea.
Lee
Young- Jung
Y
No
Kyong- Ok
K
Jung
Eun- Yong
E
Sung
Jong- Hwan
J
Kim
Yun- Bae
Y
Nam
Sang- Yoon
S
D000284:Administration, Oral; D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage / Q000633:toxicity*; D000975:Antioxidants / Q000008:administration & dosage / Q000627:therapeutic use*; D003402:Creatine Kinase / Q000097:blood; D004317:Doxorubicin / Q000008:administration & dosage / Q000633:toxicity*; D004336:Drug Antagonism; D036145:Ginsenosides / Q000627:therapeutic use*; D005979:Glutathione Peroxidase / Q000235:genetics / Q000378:metabolism; D007274:Injections, Intraperitoneal; D007770:L-Lactate Dehydrogenase / Q000097:blood; D008297:Male; D051379:Mice; D008813:Mice, Inbred ICR; D009929:Organ Size / Q000187:drug effects; D005894:Panax; D000080662:Phospholipid Hydroperoxide Glutathione Peroxidase; D012313:RNA / Q000032:analysis; D012333:RNA, Messenger / Q000187:drug effects / Q000378:metabolism; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013091:Spermatogenesis / Q000187:drug effects; D013733:Testicular Diseases / Q000139:chemically induced / Q000473:pathology / Q000517:prevention & control*; D013737:Testis / Q000187:drug effects* / Q000201:enzymology / Q000473:pathology
D000903:Antibiotics, Antineoplastic; D000975:Antioxidants; D003402:Creatine Kinase; D004317:Doxorubicin; D036145:Ginsenosides; D005979:Glutathione Peroxidase; D007770:L-Lactate Dehydrogenase; D000080662:Phospholipid Hydroperoxide Glutathione Peroxidase; D012313:RNA; D012333:RNA, Messenger; C112772:ginsenoside compound K